Vasyl A. Beniuk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Vasyl A. Beniuk has a total of 332 co-authors. Here are the top co-authors by number of shared publications:
- Mykola Ya Spivak
D.K. Zabolotny Institute of Microbiology and Virology, NAS of Ukraine, 154 Akademika Zabolotnoho Str., Kyiv, 03143, Ukraine
2 shared publications - Olga V. Kalenska
Клінічна лікарня «Феофанія» Державного управління справами, м. Київ
2 shared publications - Rostyslav Bubnov
Clinical Hospital “Pheophania”, Kyiv, Ukraine
2 shared publications - Vadym M. Goncharenko
Women’s Health Center of the Clinical Hospital “Feofaniya” of State Management of Affairs of Ukraine, Kyiv
2 shared publications Agnieszka Giemza
VIANESSE AG, Research and Development, Engelberg, Switzerland
1 shared publicationAgnieszka Migasiewicz
1 shared publication
Latest Publications
- Open Access
- 9 May 2016
- Published by Springer Nature in EPMA Journal
- Vol. 7 (S1) , 1-42
EPMA-World Congress 2015
A1 Predictive and prognostic biomarker panel for targeted application of radioembolisation improving individual outcomes in hepatocellular carcinoma Jella-
- 9 May 2016
- Published by Springer Nature in EPMA Journal
- Vol. 7 (S1) , 1-42
Open AccessEPMA-World Congress 2015
A1 Predictive and prognostic biomarker panel for targeted application of radioembolisation improving individual outcomes in hepatocellular carcinoma Jella-
- Open Access
- 6 December 2013
- Published by Springer Nature in EPMA Journal
- Vol. 4 (1) , 24
Predictive diagnosis of endometrial hyperplasia and personalized therapeutic strategy in women of fertile age
Introduction: Endometrial hyperplasia has a high risk for malignant transformation and relapses; existing mini-invasive treatments may lead to irrevocable endometrium destruction. The aims were to analyze receptor systems in endometrial hyperplasia, to evaluate the capabilities of ultrasonography, sonoelastography for diagnosis and treatment control, and to develop treatment algorithm. Materials and methods: We included 313 women (20–45 years), assessed into the following: group 1 (n = 112) with glandular cystic hyperplasia, group 2 (n = 98) endometrial polyps, and group 3 (n = 103) atypical hyperplasia; and 82 controls who have undergone hysteroscopy before in vitro fertilization in tubal origin infertility were also included. Patients underwent clinical examination, transvaginal ultrasound, immunohistochemical study, and hormonal therapy/hysteroresectoscopy. Results: In patients with glandular hyperplasia, we registered increase of endometrium estrogen receptors (75.6% in the epithelium and 30.9% in the stroma; in controls, 43.3% and 29.6%, respectively); in polyps, there was a significant estrogen receptor increase in the stroma (48.2% vs 29.6% in controls), and in atypical hyperplasia, progesterone receptors significantly increased in the stroma. Ki-67 increased (40% to 50%) in the epithelium without changes in the stroma. Ultrasound has a sensitivity of 96% and a specificity of 85% for early detection of endometrial pathology and prediction outcome of intervention, and sonoelastography has a sensitivity of 91% and a specificity of 83% for polyp diagnosis. Personalized treatment was effective in 88.8%, relapse was diagnosed in 11.2% after 6 months, and conservative treatment of atypical hyperplasia was effective in 45%: in 25.8%, ablative hysteroresectoscopy was performed, while in 22.6% with comorbidities, hystero/oophorectomies were performed. Conclusions: The evaluation of receptor status with ultrasound data in patients with endometrial hyperplasia allows for a clear definition of the treatment policy, avoidance of relapse, treatment optimization, and observation of such patients.
- 6 December 2013
- Published by Springer Nature in EPMA Journal
- Vol. 4 (1) , 24
Open AccessPredictive diagnosis of endometrial hyperplasia and personalized therapeutic strategy in women of fertile age
Introduction: Endometrial hyperplasia has a high risk for malignant transformation and relapses; existing mini-invasive treatments may lead to irrevocable endometrium destruction. The aims were to analyze receptor systems in endometrial hyperplasia, to evaluate the capabilities of ultrasonography, sonoelastography for diagnosis and treatment control, and to develop treatment algorithm. Materials and methods: We included 313 women (20–45 years), assessed into the following: group 1 (n = 112) with glandular cystic hyperplasia, group 2 (n = 98) endometrial polyps, and group 3 (n = 103) atypical hyperplasia; and 82 controls who have undergone hysteroscopy before in vitro fertilization in tubal origin infertility were also included. Patients underwent clinical examination, transvaginal ultrasound, immunohistochemical study, and hormonal therapy/hysteroresectoscopy. Results: In patients with glandular hyperplasia, we registered increase of endometrium estrogen receptors (75.6% in the epithelium and 30.9% in the stroma; in controls, 43.3% and 29.6%, respectively); in polyps, there was a significant estrogen receptor increase in the stroma (48.2% vs 29.6% in controls), and in atypical hyperplasia, progesterone receptors significantly increased in the stroma. Ki-67 increased (40% to 50%) in the epithelium without changes in the stroma. Ultrasound has a sensitivity of 96% and a specificity of 85% for early detection of endometrial pathology and prediction outcome of intervention, and sonoelastography has a sensitivity of 91% and a specificity of 83% for polyp diagnosis. Personalized treatment was effective in 88.8%, relapse was diagnosed in 11.2% after 6 months, and conservative treatment of atypical hyperplasia was effective in 45%: in 25.8%, ablative hysteroresectoscopy was performed, while in 22.6% with comorbidities, hystero/oophorectomies were performed. Conclusions: The evaluation of receptor status with ultrasound data in patients with endometrial hyperplasia allows for a clear definition of the treatment policy, avoidance of relapse, treatment optimization, and observation of such patients.